Review of clinical trials using early acute intervention with oral triptans for migraine management.
Most of the data on triptan use are from clinical trials in which patients were instructed to wait until migraine headache pain was moderate/severe in intensity. In the real world, patients may hesitate to use a triptan until headache pain is moderate/severe because of the cost of these agents or limited supply allowed by their health service organisation. However, accumulating data indicate that early intervention with an oral triptan when headache pain is still mild may be the most effective acute treatment strategy. Economic analyses also support early triptan intervention in migraine attacks. Tolerability is expected to be particularly important in early intervention, as patients treating mild migraine pain may be more reluctant to risk adverse events. Thus, an agent selected for use as early intervention should have both a demonstrated efficacy in treating mild migraine headache and placebo-like tolerability. This article reviews retrospective and prospective clinical trials which investigated the use of triptans for early acute migraine therapy.
Dowson
A J
AJ
King's Headache Services, King's College Hospital, London, UK. drandydowson@dowsona.fsnet.co.uk
Mathew
N T
NT
Pascual
J
J
D000284:Administration, Oral; D000700:Analgesics / Q000008:administration & dosage*; D002986:Clinical Trials as Topic; D006801:Humans; D008881:Migraine Disorders / Q000188:drug therapy*; D011446:Prospective Studies; D012189:Retrospective Studies; D055502:Secondary Prevention; D017366:Serotonin Receptor Agonists / Q000008:administration & dosage*; D016896:Treatment Outcome; D014363:Tryptamines / Q000008:administration & dosage*
D000700:Analgesics; D017366:Serotonin Receptor Agonists; D014363:Tryptamines